Vasopressor Initiation in Hypotensive Patients

Initial Fluid Resuscitation and Vasopressor Triggers

The American College of Critical Care Medicine and the Society of Critical Care Medicine recommend administering 30 mL/kg of crystalloid fluid within the first 3 hours for patients with septic shock or hypotension 1, 2, 3
Balanced crystalloid solutions, such as lactated Ringer's or Plasma-Lyte, are preferred over normal saline for resuscitation 3
In resource-limited settings or when pulmonary edema risk is high, consider a more restrictive initial bolus of 1-2 L, escalating to 30 mL/kg if inadequate response 3

Vasopressors should be initiated when mean arterial pressure (MAP) remains below 65 mmHg despite adequate fluid resuscitation 1, 2, 4
The Society of Critical Care Medicine recommends starting vasopressors when systolic blood pressure is not available, but signs of persistent tissue hypoperfusion, such as altered mental status, oliguria, or elevated lactate, are present 5, 4
Patients who are not candidates for further fluid resuscitation due to pulmonary edema or fluid overload should be started on vasopressors 3, 6

The American College of Critical Care Medicine and the Society of Critical Care Medicine recommend norepinephrine as the first-choice vasopressor for hypotensive shock 1, 2, 3, 7
Norepinephrine should be started at 0.02 mcg/kg/min and titrated to a MAP goal of 65 mmHg in most patients 3
An arterial catheter should be placed as soon as practical for continuous blood pressure monitoring in all patients requiring vasopressors 1, 2
Monitor for signs of adequate perfusion, including capillary refill, skin temperature, mental status, and urine output (>0.5 mL/kg/h) 5, 4

Dopamine should be avoided as a first-line agent due to increased arrhythmia risk and reserved only for highly selected patients with bradycardia and low arrhythmia risk 1, 2
Low-dose dopamine should not be used for renal protection, as it is ineffective 1, 2
In pregnant patients, standard MAP targets apply, but fetal status should be monitored when using vasopressin due to theoretical oxytocin receptor interaction 3